Hologic, Inc. v. Siemens Healthineers AG; Siemens Healthcare GmbH; Siemens Healthineers Nederland B.V.; Siemens Healthcare SAS

App_33733/2025

In a procedural order concerning the infringement and revocation of EP 2 352 431 B1, the Düsseldorf Local Division addressed issues of trade secret protection. The court granted the request to classify certain information regarding the design and functioning of the attacked embodiments as confidential under Art. 58 UPCA. This decision reinforces the mechanism for protecting sensitive commercial data during complex UPC litigation involving major medical device manufacturers.

Jurisdiction
European UPC
Court
Düsseldorf (DE) Local Division
Case Number
App_33733/2025
Judge(s)
Thomas on behalf of Judge Dr Thom acting as judge

What the Court Held — Ratio Decidendi

The Court of First Instance granted the application for protecting confidential information under Art. 58 UPCA and R. 262A RoP, finding that the grounds significantly outweighed the interest in full public access. The court also lifted prior access restrictions on certain documents submitted by the Claimant.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before Düsseldorf (DE) Local Division. Understanding the court's reasoning in Hologic, Inc. vs Siemens Healthineers AG; Siemens Healthcare GmbH; Siemens Healthineers Nederland B.V.; Siemens Healthcare SAS is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentUPC_CFI_404/2025

Edwards Lifesciences CorporationvsMeril GmbH a.o.

In this cost decision case, the UPC Local Division Munich ruled in favor of Edwards Lifesciences Corporation against Meril GmbH and its affiliates. The court awarded a substantial sum of EUR 771,649.56 to cover Edwards' legal costs incurred during the proceedings related to EP patent 3669828. The ruling emphasized that given the overall complexity of the case, the judge-rapporteur has broad discretion and may award costs even if specific disputed elements (like travel details) are marginal.

patentORD_16076/2024

Avago Technologies International Sales Pte. LimitedvsTesla Germany GmbH; Tesla Manufacturing Brandenburg SE

In this UPC case, Avago Technologies sued Tesla entities for infringement of EP1838002. Concurrently, the defendants filed counterclaims seeking revocation of the patent. The court issued an order consolidating all claims—the main action and both counterclaims—to be heard together before the Munich Local Division. This procedural step streamlines the litigation process by addressing infringement and validity simultaneously.

patentORD_44387/2024

Mammut Sports Group AGvsOrtovox Sportartikel GmbH

This UPC appeal decision addressed procedural matters within a patent infringement case involving Mammut and Ortovox regarding an LVS device (EP 3 466 498). The court focused heavily on the scope of appeals concerning interim measures, clarifying that arguments must be clearly presented in the initial filing. While the core dispute was about patent validity/infringement, the ruling ultimately dismissed Mammut's appeal and ordered them to cover additional provisional costs.

patentORD_598366/2023

Meril Italy SrlvsEdwards Lifesciences Corporation

In a significant UPC decision, the Central Division rejected revocation actions against Edwards Lifesciences Corporation concerning its prosthetic heart valve patent (EP '825). The claimants argued for invalidity based on lack of novelty and inventive step. However, the Court maintained the patent's validity after accepting an amendment submitted by the defendant, underscoring the importance of procedural compliance in UPC litigation.

patentApp_33491/2024

Edwards Lifesciences CorporationvsMeril Lifesciences PVT Limited; Meril GmbH; Smis International OÜ; Sormedica UAB

This procedural order addressed a request by an applicant (a member of the public/investor) seeking broad access to pleadings and evidence in ongoing UPC infringement cases. The Court denied this access, emphasizing that the integrity of private civil litigation must be protected until proceedings conclude. While denying the immediate request, the Court granted leave to appeal, recognizing the importance of clarifying the legal interpretation regarding public access under RoP 262.1(b).

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call